# PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Source: https://onco.cc/trials/nct06245889/  
OnCo record `nct06245889` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of paclitaxel / nab-paclitaxel, carboplatin, pembrolizumab, doxorubicin and other drugs in triple-negative breast cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.

## Summary

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC is a phase 2, interventional study registered as NCT06245889 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with a registry enrolment figure of 30 participants, started 2024-05-01 and due to reach its primary completion in 2029-06. Interventions recorded: Paclitaxel; Carboplatin; Pembrolizumab; Doxorubicin; Cyclophosphamide; Olaparib; Capecitabine. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Stage II-III TNBC - estrogen receptor (ER) and progesterone receptor (PR) up to and including 10% is eligible". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: NeoADAPT
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06245889
- Phase: 2
- Setting: A Pilot Study of Neoadjuvant Response-Adapted Chemotherapy With Pembrolizumab in Patients With Stage 2 and 3 Triple Negative Breast Cancer to Determine Early PET and Biomarker Dynamics
- Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06245889: https://clinicaltrials.gov/study/NCT06245889

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Olaparib](https://onco.cc/drugs/olaparib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06245889.json